Obstructive sleep apnea is a sleep breathing disorder characterized by recurrent and intermittent hypoxia with continued respiratory effort against a closed glottis. The result of this is a cascade of acute and chronic systemic pathophysiological responses that cause endothelial dysfunction, atherosclerosis and lead to cardiovascular and cerebrovascular disease. This article focuses on the clinical evidence linking obstructive sleep apnea and stroke and on the specific mechanisms perpetuating stroke risk in this population.
Introduction
Stroke is a devastating illness and the second leading cause of death worldwide. The vast majority of strokes are ischemic and result from a transient or permanent reduction in cerebral blood flow to a specific territory of brain. Primary prevention of stroke is key as the effect of stroke is devastating with an immediate energy failure of the brain tissue involved at the core of the ischemic territory, followed by activation of glutamate receptors, excitotoxicity, inflammation and programmed cell death. 1 The ischemic penumbra is an area surrounding the infarct core, which is potentially salvageable. Recovery is possible in stroke by plasticity and tissue reorganisation. In those who have sustained a stroke, the minimisation of brain injury and prevention of a subsequent recurrence is crucial to the reduction of morbidity and mortality. Despite newer treatment strategies (eg, thrombolysis) the mortality from stroke is unchanged over the last 5-10 years. 2, 3 Morbidity from stroke is substantial with 20% of survivors requiring institutional care and 15%-30% having permanent disabilities. Despite newer primary and secondary treatment strategies the incidence of stroke is rising worldwide.
Obstructive sleep apnea (OSA) is prevalent in the general population occurring in 24% of men and 9% of women in the population. 4 OSA is a sleep breathing disorder in which there is continued respiratory effort with recurrent intermittent partial or complete collapse of the pharyngeal airway resulting in partial or complete cessation of airflow. Worldwide obesity (body mass index [BMI] $ 30 kg/m 2 ) is now the fifth leading risk of death with more than 10% of the adult population considered obese. 5 Studies have consistently demonstrated that weight is the strongest risk factor for OSA. 6, 7 It is therefore probable that a considerable percentage of the population have undiagnosed and untreated OSA.
In an era when modern medicine is targeting primary prevention of diseases, this cohort of individuals possibly represents a lost opportunity for disease modification and prevention.
To help elucidate the potential role of OSA as a significant risk factor for stroke, I will review the available epidemiological evidence, whether or not treatment of OSA affects outcome and the pathophysiological processes linking OSA to stroke.
Evidence for OSA predating stroke
As with the association between OSA and cardiovascular disease (eg, atrial arrhythmias), exploration of the bidirectional nature of the disease has occurred. This is particularly pertinent to OSA and stroke, as brain damage to the respiratory control centre may cause sleep disordered breathing in a small number of cases. 8 However, there is accumulating evidence in the literature for the presence of OSA prior to the occurrence of strokes.
A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by focal brain, spinal cord or retinal ischemia without acute infarction. 9 As TIAs are the precursor to stroke in up to 33% of patients, with a 90 day risk of stroke at 10.5%, 10, 11 if OSA is present in this population, it argues for pre-existing OSA in stroke sufferers. Case reports and series suggest a high prevalence of OSA in subjects with TIA (62%-69%). [12] [13] [14] A recent study has shown that OSA occurs in 43% of patients with acute TIAs, persists in the majority of cases at 90 days and is associated with a higher vascular event rate when untreated. 15 Contradicting this is a matched case-control study which failed to show any significant difference in the frequency of OSA between the control and TIA groups. 16 While there are conflicting reports regarding OSA in TIA patients, the majority of the studies show an increased prevalence in this population suggesting the pre-existence of OSA in stroke patients.
Secondly, a recent small study of acute stroke patients both with and without OSA demonstrated a shorter retropalatal distance in the OSA group compared to the non-OSA group. This suggests that pre-existing anatomical factors and not solely alterations in neuromuscular control or increased supine sleep as a consequence of a stroke contributed to stroke in these individuals. 17 Finally, both the persistence following neurological recovery, and the absence of difference in frequency of OSA between brainstem and hemispheric strokes, the fact that OSA is more common in those with recurrent stroke, suggests that OSA may predate the development of stroke in a significant percentage of the stroke population.
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Initial observations regarding link between OSA and stroke
Clinical observations are the initial primer for most research, and the link between OSA and stroke was first described in a 1985 case report of a 34-year-old man with an acute stroke diagnosed with severe OSA. 19 There was a subsequent retrospective case series in 1991 which found a prevalence of OSA in stroke patients of 72%, 53% and 30% when using apnea-hypopnea index (AHI) of $10, 20 and 30 respectively. 20 Following these initial reports there were a series of prospective case studies and case-control studies that all reported similar high prevalences of OSA in stroke patients. This was confirmed in a meta-analysis of 29 studies which included 2343 stroke subjects, demonstrating the presence of OSA in 72% with an AH . 5 events per hour and 38% with an AHI . 20 events per hour. 18 Although these studies demonstrate an association between OSA and stroke this does not prove causality. The first evidence of a link between OSA and stroke was from a series of case-control and cross-sectional analyses of epidemiological studies using snoring as a surrogate marker for OSA. These reported increased prevalence and incidence of strokes in snorers. [21] [22] [23] [24] [25] In the largest of these prospective studies, 71,779 women were followed for 8 years during which 398 strokes were documented. Habitual snoring increased the adjusted odds ratio of stroke by 1.33 (95% CI, 1.06-1.67). 26 In 2001, the Sleep Heart Health Study, a community based study of 6424 subjects who had unattended home-based sleep studies, explored the relationship between sleep-disordered breathing (SDB) and self-reported cardiovascular disease including stroke. In those in whom the respiratory disturbance index (RDI) was $11 there was an increased risk of prevalent stroke (odds ratio 1.58, 95% CI 1.02-2.46). However, this association failed to retain significance following adjustment for BMI and hypertension. 27 Subsequently data from 1475 subjects of the population based Wisconsin cohort study demonstrated a 3-fold increased adjusted risk of prevalent stroke in those with an AHI $ 20 events/hour. 28 This included adjustment for age, sex, BMI, alcohol, smoking, hypertension and diabetes. These investigators then performed a prospective analysis of the same cohort, excluding those subjects with prior stroke.
In the 4 year "prospective" analysis 14 subjects were found to have suffered a first-ever-stroke with an overall incidence of 1.33 per 1000 person-years. In the unadjusted model and in a model controlled for age and gender, subjects with a baseline AHI $ 20 had a 4-fold increased risk for an incident stroke. However, following adjustment for BMI although there was a 3-fold increased risk of stroke it failed to maintain statistical significance. The study's statistical power was limited by the small number of strokes. 
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More recently, the Sleep Heart Health Study also examined the relationship between untreated OSA and incident stroke in 5422 subjects without prior stroke over an 8 year period. 29 193 subjects suffered an ischemic stroke, with an overall incidence of 4.4 strokes per 1000 person-years in men and 4.5 strokes per 1000 years in women. In men, there was an almost 3-fold increased risk of stroke in those with an obstructive AHI . 25. Furthermore, for every one unit increase in the obstructive AHI in men there was a 6% increase in stroke risk. In women, the increased stroke risk was not observed until the obstructive AHI was .25. In both men and women the increased stroke risk was associated with increasing age, systolic blood pressure, use of antihypertensive medications and atrial fibrillation.
In a North American observational clinic cohort study 1022 subjects both with and without OSA were followed for a median time of 3.3 (no sleep apnea) or 3.4 (with sleep apnea) years. 30 In the OSA group the incidence of stroke or death was 3.48 per 100 person-years and in the control group 1.60 per 100 person-years. Following adjustment for sex, race, smoking status, alcohol, BMI, presence of diabetes mellitus, hyperlipidemia, atrial fibrillation and hypertension, OSA remained a significant independent predictor of stroke or death. There was also a significant trend with increasing OSA severity.
While both the Sleep Heart Health Study and Wisconsin cohort study have evaluated primarily middle-aged adults, the Vitoria Sleep Project, a Spanish cohort study, examined the risk of ischemic stroke in an elderly population with untreated OSA. 31 394 subjects participated in the second phase of the study and were followed for a mean period of 4.5 years. There were 20 ischemic strokes verified during the follow-up period for an incidence of 11.28 per 1000 person-years. This also demonstrated a significant association between severe OSA and ischemic stroke (hazard ratio 2.52).
In a population with symptomatic coronary artery disease and OSA there was also a significantly increased risk of stroke (adjusted hazard ratio of 2.89), independent of age, BMI, left ventricular function, diabetes mellitus, gender, intervention, hypertension, atrial fibrillation, smoking, and a previous stroke or transient ischemic attack. 32 Whether OSA is an independent predictor of stroke is still a matter of some debate. However, evidence from epidemiology and clinic based studies certainly favours OSA as having a role in the occurrence of stroke. Not only may OSA be instrumental in causing strokes but there is also evidence that in those with OSA outcomes following a stroke may be poorer.
Impact of OSA on stroke outcome
Determination of successful outcome from stroke is based on the ability of an individual to manage independently and to do activities of daily living (functional outcome), to have good quality of life and longer survival. Studies in stroke patients with OSA have shown poorer functional outcomes post stroke at 3 and 12 months, longer hospitalizations and rehabilitation, 33, 34 increased stroke recurrence 35 and increased mortality. [36] [37] [38] [39] [40] In a 10 year follow-up study of stroke patients both with and without OSA, the presence of OSA (defined as an AHI $ 15 events/hour) increased the risk of death by 75% independent of many confounders (age, sex, smoking, BMI, hypertension, diabetes mellitus, atrial fibrillation, cognition and dependency during daily living). 41 Martinez-Garcia also demonstrated in a 5 year follow-up of stroke patients with moderate-severe OSA an increased mortality compared to both those with OSA treated with CPAP and those without OSA. 42 More recently the same group showed that in stroke patients with untreated moderate-severe OSA (AHI $ 20 events/hour) there was an increased incidence of recurrent ischemic stroke independent of other cardiovascular risk factors, age and gender over a 7 year follow-up period. Furthermore, in those stroke subjects with moderate-severe OSA treated and compliant with CPAP, the risk of cardiovascular events was similar to that of those with mild OSA or without OSA. 43 However, studies on the treatment of OSA post-stroke have been somewhat disappointing. There has been poor adherence and compliance with CPAP in the stroke population. Acceptance of CPAP has varied from 15% to 80% in different studies. 36, 38, 44, 45 Multiple factors are responsible for this poor tolerance, including cognitive problems, post-stroke depression and physical disabilities limiting the application of headgear. 46 However, CPAP has been shown to be feasible in both the acute, 47,48 subacute, 49, 50 and chronic phase of stroke. [51] [52] [53] There have been five randomized controlled studies examining the effect of CPAP on stroke outcomes (Table 1) .
Parra and colleagues performed a randomized controlled trial in acute stroke subjects with OSA (AHI $ 20), in which 71 subjects were randomized to CPAP and 69 subjects were randomized to conventional treatment. Twenty eight percent of those randomized to CPAP refused to use it. In those randomized to CPAP compared to conventional treatment, there was a significant improvement in neurological recovery at 1 month and a delay in the occurrence of subsequent cardiovascular events, but no significant change in quality of life or mortality at 24 months. 38 Bravata et al randomized stroke patients to auto-titrating (auto)-CPAP or conventional therapy, and showed that at 30 days those in the treatment arm demonstrated a significant improvement in stroke severity. Furthermore, the greatest improvements were observed in those patients with the most auto-CPAP use ($4 hours for 75% of the time). 54 Hsu et al performed a randomized trial in patients with OSA (AHI $ 30) with subacute stroke (14-19 days post stroke). 44 Fifteen patients were randomized to CPAP and 15 to conventional stroke treatment. At 3 months follow-up no significant difference in functional outcomes or depressive symptoms was demonstrated. However, overall compliance with CPAP was very low and the average CPAP compliance was 1.4 hours per night. Sandberg et al randomized 59 patients with subacute stroke to CPAP or conventional therapy. Those randomized to CPAP had fewer depressive symptoms, but no change in outcome compared to the conventional group. 52 Ryan et al, in a randomized study of 44 patients with subacute stroke undergoing rehabilitation showed significant improvements in motor function and the affective component of the depression score, but not in neurocognitive function following 1 month of CPAP. 45 Therefore, in those stroke patients who comply with CPAP treatment, early improvements in motor function and mood are demonstrated, but no significant impact in long-term outcome has been demonstrated to date. All of these studies are limited by small numbers, comorbid medical conditions and the heterogenous nature of stroke.
Treatment of OSA with bilevel positive airway pressure has been assessed. An observational study assessing the treatment of acute stroke in a cohort of subjects with persisting proximal neurological occlusions with worsening during sleep, OSA or a history of OSA with bilevel positive airway pressure, demonstrated good tolerability and possible early neurological improvement. 55 A very small study on ten subjects with transnasal insufflation (a high-flow rate of air at 18 L/min delivered through an open nasal cannula) showed good tolerability, however, minimal improvements in the AHI. 56 Much larger and long-term studies will be necessary to determine the full impact of OSA treatment on patients with stroke.
Mechanisms linking OSA and stroke
OSA and sleep
Sleep has specific effects on both the autonomic and cardiovascular system. During non-rapid eye movement (NREM) sleep, respiration is almost exclusively under 
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OSA and stroke chemoreflex control, parasympathetic nervous system tone increases, and sympathetic nervous system activity, heart rate, blood pressure, stroke volume, cardiac output and systemic vascular resistance decrease. [57] [58] [59] [60] As a result, the cardiovascular system is in a state of hemodynamic and autonomic quiescence. During rapid eye movement (REM) sleep, breathing becomes more dependent on behavioral factors [61] [62] [63] and there is an irregular pattern of breathing, and intermittent surges in heart rate, sympathetic nervous activity and blood pressure linked to phasic REM sleep events. 57, 60, 63 NREM sleep represents 75% to 85% of sleep and it means that overall sleep is a period of cardiovascular quiescence. This may explain the lower occurrence of cardiovascular and cerebrovascular events during the night and the surge that occurs in the early morning between 6 am and noon in association with elevations in blood pressure and heart rate. 64, 65 However, the presence of OSA dramatically changes the normal sleep milieu and may be a factor in the higher occurrence of stroke during sleep or in the first hour of wakening in OSA subjects, reported in recent studies. [66] [67] [68] In OSA there are both acute and chronic effects that may develop over time, both may predispose to the development of stroke. These mechanisms involved in the causation of stroke and sleep apnea remain incompletely understood.
However, to understand why sleep apnea poses a potential risk for stroke, it is important to have some understanding of these pathophysiological effects of OSA. The effects of OSA may occur acutely or over time (Figure 1 ).
Acute effects of OSA
In OSA there is recurrent arterial desaturation alternating with normoxia, resulting in systemic hypoxemia and hypercapnia. Hypoxia may reduce myocardial oxygen delivery, directly depress myocardial contractility and increase left ventricular (LV) afterload, and indirectly cause increased pulmonary vasoconstriction and increasing pulmonary arterial pressure. 69, 70 Hypocapnia, as a result of post-apneic hyperventilation, can induce coronary vasoconstriction and a leftward shift of the oxyhemoglobin curve reducing oxygen release to the myocardium. 71 Hypoxia-induced ischemia of myocardial tissue induces electrical, mechanical and biochemical dysfunction particularly in those with pre-existing cardiac dysfunction. Ischemia induced increases in intracellular Ca 2+ and H + , accumulation of lipid metabolites and dephosphorylation of gap junction protein connexin 43 causes electrical uncoupling and triggers arrhythmias. 
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Arousals are critical to the opening of the upper airway and resumption of ventilation in OSA. 74, 75 They may contribute to post-apneic surges in heart rate and blood pressure, [76] [77] [78] sympathetic nervous system activation and catecholamine release. 74, 79 Repetitive arousals may contribute to increased sleep fragmentation and neurocognitive sequelae.
Futile inspiratory effort against a closed glottis as occurs in OSA results in the generation of negative intrathoracic pressure to as low as -108 cm H 2 O. 80 These swings in pressure result in increased venous return to the right heart with subsequent distension of the right ventricle and leftward shift of the interventicular septum during diastole. 70 This adversely affects filling of the LV and causes reduced stroke volume, and delay LV relaxation. 81 In turn, this may cause reductions in cerebral blood flow. [82] [83] [84] The increased transmural gradients may promote excessive vessel shear stress and promote endothelial dysfunction.
Chronic effects of OSA Autonomic dysfunction
The repetitive arousals and intermittent hypoxia cause overactivation of the sympathetic nervous system, reduced baroreflex sensitivity and heart rate variability and increased blood pressure variability in subjects with OSA through the stimulation of peripheral and central chemoreceptors. 79, 85 In animal studies noradrenaline has been demonstrated to result in hypertrophy of the myocardium. 86 There is a correlation between increased sympathetic nervous activity (SNA) and left ventricular hypertrophy in subjects with hypertension, suggesting that increased SNA may contribute to myocardial remodeling in humans. 87 Elevated SNA may perturb cerebral autoregulation and blood flow predisposing to cerebral ischemia. 88 Evidence from post-stroke subjects demonstrates that elevated serum noradrenaline is an independent predictor of poor outcome at 1 year. 89 
endothelial dysfunction and atherosclerosis
The cyclic intermittent hypoxia is akin to a chronic ischemiareperfusion type injury that may have a direct effect on the vasculature. This oxygenation/reoxygenation injury is known to initiate oxidative stress via the production of reactive oxygen species (ROS). Increased oxidative stress denotes an imbalance between ROS production and antioxidant defence. This is recognized to play an important role in the genesis of endothelial dysfunction, via inactivation of vasodilator nitric oxide (NO) 90 and through the modulation of diverse redoxsensitive signaling pathways in endothelial cells which influence gene and protein expression. 91 The redox-sensitive signaling pathways include nuclear factor kappa β (NF-κB) and hypoxiainducible factor-1 (HIF-1). NF-κB activates pro-inflammatory cytokines (TNFα, IL-6), chemokines (MCP-1 and IL-8) and adhesion molecules (ICAM, VCAM, selectin).
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There is increasing evidence that vascular wall inflammation plays a key role in the pathogenesis of vascular disease and the atherosclerotic process. 93 Functional impairment signifies endothelial dysfunction, a precursor of atherosclerosis, whereas in atherosclerosis there are structural changes in the arterial walls. Vascular tone is usually maintained by the homeostatic balance between vasodilators (nitric oxide and prostacyclin) and vasoconstrictors (endothelin-1 and angiotensin II). There is good evidence that OSA is associated with endothelial dysfunction. 94 Lavie and Lavie have proposed oxidative stress as the unifying mechanism between OSA and vascular disease and its associated comorbid illnesses. 95 However, whether oxidative stress is a consequence or a cause of OSA is still controversial. 96 In vitro models of intermittent hypoxia were the first to demonstrate activation of NF-κB 97 and suggest a causative pathway between OSA and inflammation. The presence of increased oxidative stress in OSA has been assessed indirectly by markers such as oxidized LDL and thiobarbituric acidreactive substance (TBARS). The vast majority of studies in OSA have demonstrated increased oxidative stress, while only a few have failed to show this increase. 95 Non-randomized uncontrolled studies have also demonstrated activated NF-κB and elevated levels of its associated proinflammatory cytokines, chemokines and adhesion molecules in OSA patients, consistent with the animal models of intermittent hypoxia. 98 Reduction in these markers is demonstrated following CPAP treatment. [99] [100] [101] There is also an association between OSA and elevated levels of matrix metalloproteinase-9, which is activated by oxidative stress, and induces plaque rupture. 102 Matrix metalloproteinases are known to disrupt the blood-brain barrier in stroke. 103 While most studies in OSA have concentrated on investigating the deleterious effect of oxidative stress on the cardiovascular system, the brain is highly susceptible to oxidative damage due to the paucity of its antioxidant system and large oxygen dependency. 104, 105 There is limited evidence from animal studies of ROS production causing neuronal injury. 106 Furthermore, in a study of 50 nonobese subjects with stroke and OSA there were increased IL-6 levels compared to a control group. The IL-6 levels were independently correlated with the oxygen desaturation index and low oxygen saturation, but not with the AHI. This may suggest inflammation as an important unifying mechanism between OSA and stroke. 107 
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The intermittent hypoxia/reoxygenation of OSA also affects the function of both neutrophils and leukocytes further stimulating inflammation and atherogenesis. Evidence from Lavie and colleagues demonstrated a reduction in neutrophil apoptosis and increased selectin adhesion molecule expression in moderate-severe OSA patients that was improved by treatment with nasal CPAP. 108 Delayed apoptosis of neutrophils may facilitate the increased production of ROS and hence stimulate atherogenesis. This group has also demonstrated increased activation of monocytes, CD4, CD8 and γδ T cells with subsequent release of ROS and endothelial cell damage. [109] [110] [111] The chronic intermittent hypoxia of sleep apnea is probably responsible for activation of the renin angiotensin aldosterone system (RAAS) as demonstrated in animal studies. 112, 113 The RAAS is a hormonal system that controls body fluid volume, blood pressure and cardiovascular function. Angiotensin II is synthesized by and locally active on the endothelium. High plasma levels of aldosterone and angiotensin II are reported in patients with OSA. 114 Angiotensin II causes an increased production of reactive oxygen species via the NADH/NADPH oxidase activation. 115 Both hypoxia and angiotensin II are potent stimulators of the angiogenic cytokine vascular endothelial growth factor (VEGF), a contributor to atherogenesis. 116 This RAAS activation may also contribute to elevations in blood pressure. 117 Therefore, overactivity of RAAS may stimulate hypertension a risk factor for stroke.
Chronic hypoxia of OSA is also implicated in the induction of hyperlipidemia and lipid peroxidation, initiation or potential aggravation of insulin resistance and diabetes mellitus through the ROS. However, the relationship between OSA and insulin resistance is still disputed. 118 As insulin has vasodilatory and anti-inflammatory effects, 119 , insulin resistance may alter the homeostatic balance in favour of the development of atherosclerosis. Hyperglycemia and hyperinsulinemia activate the RAAS and facilitate the generation of ROS via an NADPH oxidase mechanism leading to oxidative injury. 120 In summary, the nocturnal cyclic intermittent hypoxia of OSA activates systemic inflammation, oxidative stress and metabolic dysfunction which are potential precursors of endothelial dysfunction and atherosclerosis. These are complex interrelated pathways and mechanisms which have as yet to be fully elucidated.
As atherosclerosis is a marker of incident stroke, [121] [122] [123] [124] if OSA predisposes to atherosclerosis then it suggests another mechanistic pathway by which it may cause stroke.
There have been a number of studies by Drager and colleagues evaluating the role of OSA in atherosclerosis in patients compared to controls. Firstly, compared to controls, those OSA patients on no medications and without comorbid conditions had early signs of atherosclerosis. 125 Secondly, when OSA subjects were compared to those with hypertension, there was similar atherosclerosis with an additive effect seen in those subjects with both OSA and hypertension. 126 Furthermore, a randomized controlled trial demonstrated reductions in atherosclerosis following 4 months of CPAP treatment. 127 There have been numerous other cross-sectional studies that have echoed these findings, suggesting that OSA may be an independent predictor of atherosclerosis. 118 In ischemic stroke patients, severe OSA has been shown to have a strong association with extracranial artery disease and peripheral arterial disease. 128 Furthermore, a prospective study of 214 ischemic stroke patients demonstrated that OSA was an independent risk factor of atherosclerotic artery disease independent of other vascular risk factors. 129 
Hypertension
Hypertension increases the risk of stroke 3 to 4 fold and is a major modifiable risk factor for stroke. 130 Hypertension induces remodelling of systemic and cerebral blood vessels and promotes atherosclerosis. 131 In normal subjects there is a reduction in nocturnal blood pressure compared to wakefulness by 10%-20%. This is called nocturnal dipping of the blood pressure. Attenuated nocturnal blood pressure dipping has been associated with greater leukoaraiosis. 132 The Dublin Outcome Study has shown that a 10% increase in nocturnal systolic blood pressure was associated with a 21% increase in cardiovascular morbidity 133 and a meta-analysis of randomized controlled trials on the treatment of hypertension demonstrated that for a 10 mm Hg reduction in SBP and 5 mm Hg reduction in DBP there was a 41% relative risk reduction in stroke. 134 In OSA, hypertension may result from intermittent hypoxia associated activation of the RAAS, sympathetic activation, 70, 85 altered chemoreceptor sensitivity 135 and up-regulation of endothelin-1 receptors. 136 Evidence in support of OSA as a cause of hypertension includes: (1) the dose-dependent linear relationship between OSA and elevated arterial blood pressure; 137 (2) crosssectional studies demonstrating an increased risk of prevalent hypertension in those with OSA; (3) a reduction in blood pressure in OSA subjects treated with CPAP. [138] [139] [140] Both 
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Ryan between OSA and prevalent hypertension following adjustment for confounders including obesity. 137, 141 The Wisconsin cohort study, a population-based study, demonstrated a 3-fold increased risk of incident hypertension following adjustment for body mass index in OSA subjects with an AHI . 15 events per hour. 142 However, the Sleep Heart Health study failed to demonstrate that OSA was a significant risk factor for incident hypertension following adjustment for BMI. 143 In patients with resistant hypertension the prevalence of OSA is high at 83% 144 and OSA may be an independent predictor. 145 Treatment of OSA by CPAP has been demonstrated to have modest effects in the reduction of blood pressure. [138] [139] [140] Following an acute stroke, alterations in blood pressure control occur. There is a loss of circadian variation with an absence of the nocturnal dipping and the presence of low or high blood pressure is associated with poorer outcomes. [146] [147] [148] [149] In subjects with OSA and acute stroke there is greater blood pressure variability, 39 a factor known to be associated with poorer outcomes. A small prospective study of 41 subjects with sleep apnea and an ischemic stroke showed that severe sleep apnea (AHI . 30) was associated with greater 24 hour blood pressure values. 150 However, larger studies are necessary to evaluate more fully the impact of OSA on acute stroke both in the short and long term.
Hypercoagulability
Hypercoagulability may predispose to acute thrombosis and subsequent cerebrovascular events. 151, 152 Altered hypercoagulability occurs by a variety of mechanisms in OSA. Studies to date have demonstrated alterations in platelet activation, plasminogen activator inhibitor-1 (PAI) and fibrinogen in OSA subjects but are not conclusive. Increased platelet aggregability and markers of hypercoagulation including plasma fibrinogen, plasma viscosity and d-dimers, erythrocyte adhesiveness, and PAI have been demonstrated in sleep disordered breathing [153] [154] [155] with reductions in nonrandomized studies following CPAP.
156,157 RAAS activation and hypoxia may contribute to activation of PAI 158 in OSA. Platelet, coagulation factors and fibrinogen follow a circadian pattern. Platelet aggregation increases between 6 am and noon. Tissue-type plasminogen activator concentrations and PAI peak after 6am causing reductions in fibrinolytic activity. However, in OSA, peaks in these factors occur during the night. [159] [160] [161] [162] Therefore, in OSA there may be exaggeration and shift in the timing of the usual circadian variation in platelet aggregability and markers of hypercoagulation.
Arrhythmias
A number of serious cardiac arrhythmias have been described in association with OSA including sinus pauses, heart block, atrial and ventricular tachycardia. 163 In OSA, the generation of negative intrathoracic pressure will cause stretch and remodeling of the atria and pulmonary vein ostia predisposing to conduction abnormalities.
In a cross-sectional analysis of the Sleep Heart Health Study, a prospective epidemiology trial, there was a 4-fold increase in atrial fibrillation, 3-fold increase in non-sustained ventricular tachycardia and 2-fold increase in the odds of complex ventricular ectopics in those with severe sleep disordered breathing (respiratory disturbance index $ 30) compared to those without, after adjustment for potential confounders including BMI, age, sex and prevalent coronary heart disease. 164 In the MrOS study a strong association between sleep apnea and arrhythmia occurrence was also noted. 165 Atrial fibrillation is a major risk factor for stroke. While the first association between atrial arrhythmias and sleep apnea occurred in the 1980s, 166 it has been in the last few years that there has been an explosion of research assessing the link between OSA and atrial fibrillation.
Kanagala et al demonstrated prospectively that in a group of patients undergoing DC cardioversion for atrial fibrillation there was an increased recurrence rate in those with either untreated OSA or non-compliant with OSA therapy (82%) compared with those compliant (42%, P = 0.013) and those without OSA (53%, P = 0.009). 167 In patients without cardiac disease or known arrhythmias the prevalence of atrial arrhythmias in 247 patients with OSA (defined as AHI . 5/hour) was 6.1% with less than 1% with atrial fibrillation. 168 More recently a population-based Japanese study demonstrated an association trend between the severity of OSA as defined by the 3% oxygen desaturation index (ODI) and atrial fibrillation following adjustment for age, BMI, smoking, systolic hypertension and antihypertensive medications. The adjusted odds ratio for mild (ODI 5-15/hour) was 2.47 and 5.66 for moderate to severe SDB (ODI $ 15/hour). The adjusted prevalence for atrial fibrillation was 1.9% for mild SDB and 4.9% for moderatesevere SDB (P , 0.001). 169 In a retrospective study of 3542 subjects for the occurrence of incident atrial fibrillation OSA was present in 74% of the subjects and there was a mean follow-up of 4.7 years. The presence of OSA (AHI . 5) was a strong predictor of incident atrial fibrillation (HR 2.181-3.54, P = 0.002). Atrial fibrillation occurred in 4.3% with OSA and 2.1% without OSA. 
51
OSA and stroke
Patent foramen ovale
Patent foramen ovale (PFO) is prevalent in the general population, occurring in 27%-35% of hearts at autopsy and in 10%-26% of individuals undergoing transesophageal echocardiography (TEE) with contrast. 171 PFO is significantly associated with cryptogenic stroke in both young and old subjects. 172 The prevalence of PFO in stroke varies between 20%-54%. Increased stroke risk in those with PFO is associated with the magnitude of the right to left shunting, size of the PFO and other factors such as the excursion of the interatrial septa into either atrial cavity, persistent Chiari networks, prominent Eustachian valves 171 and prothrombotic state. 173 Obviously due to the high prevalence in the general population both OSA and PFO may coexist. There have been three small studies done that have reviewed the prevalence of PFO in OSA. Prevalences of PFO were variable (26.9%-68.8%), with two studies suggesting increased prevalence compared to the general population. 174, 175 Furthermore, in subjects with PFO and OSA, right to left shunting was observed during obstructive apneas lasting .17 seconds 175 and there may be more severe nocturnal oxygen desaturation. The negative intrathoracic pressure which occurs during apnea episodes leads to increased venous return to the right heart which favours right to left shunting. Therefore, the combination of a PFO and OSA may predispose to increased stroke risk by potentially causing paradoxical embolism and increased right to left shunting.
Physical inactivity
Regular physical activity has been documented to have beneficial effects for stroke reduction in both men and women in several epidemiological and cardiovascular long-term studies. 176 Mediation of this stroke risk reduction in association with physical activity may occur by reductions in blood pressure, weight, diabetes and reduced fibrinogen and platelet activity. 177, 178 In two cross-sectional studies, physical inactivity is significantly associated with OSA following adjustment for confounding variables including age, BMI and sleepiness. 179, 180 However, in an APPLES sub-study, the reduction in physical activity in the OSA group was primarily explained by decreased physical activity related to obesity, 181 although the number of subjects in this study was considerably smaller than in the Wisconsin cohort study. 180 In a double blind parallell randomized controlled trial in which OSA subjects were treated with CPAP or placebo, there was no increase in physical activity observed in the treated OSA subjects despite a reduction in sleepiness. The authors conclude that this may be due to longstanding habitual patterns in these patients. 182 More recent evidence linking physical inactivity to OSA has come from Bradley and colleagues. 183 In evaluating the role of fluid shifts in the pathogenesis of OSA they have also shown that in those who spend greater periods of the day sitting (physically inactive) there is increased shift of fluid from the legs to the neck overnight which is strongly linked to the AHI. 183 
Brain injury
In order to meet its metabolic demands the brain is highly dependent on an adequate cerebral blood flow. Cerebral blood flow changes in response to cerebral perfusion pressure, PaCO 2 , PaO 2 , arterial oxygen content and blood viscosity. Changes in cerebral perfusion pressure over a wide range, from 50 to 170 mm Hg, have little effect on cerebral blood flow. Cerebral autoregulation is the compensatory mechanism by which cerebral blood flow remains relatively constant during variation of cerebral perfusion pressure from 50 to 170 mmHg. It is mediated by changes in cerebrovascular resistance. Cerebral autoregulation is a complex homeostatic mechanism that is dependent on multiple factors including myogenic, neuronal, endothelial and metabolic. It remains unaltered with age and hypertension. However, it has been shown to change under physiological and pathological conditions such as exercise, stroke, and carotid artery disease. Cerebral blood flow responds to increases in PaCO 2 by vasodilation and a subsequent increase in cerebral blood flow and to decreases in PaCO 2 by vasoconstriction and a subsequent decrease in cerebral blood flow (cerebrovascular reactivity). Cerebral blood flow is less responsive to changes in blood viscosity and does not increase until PaO 2 is reduced below 50 mm Hg.
Decreased cerebral blood flow velocity during wakefulness and during apneas in OSA subjects has been demonstrated. [82] [83] [84] It is not clear whether the intermittent hypoxia, or reduction in blood flow as a result of OSA, or possible increases in perfusion pressure or shear stress are the mediators of potential ischemic brain injury. A recent large population-based study of OSA subjects has shown impaired daytime hypercapnic cerebrovascular reactivity in a continuum from mild to severe OSA. 184 In view of the recurrent nocturnal hypoxia in OSA and the risk of recurrent hypoxic insult, protection of the brain is dependent on an adequate cerebral vascular response. Failure of the cerebral circulation to respond to hypoxia or hypercapnia may result in hypoperfusion of the brain, 88 leading to impaired neural function and an increased risk of cerebral ischemia and stroke. Impaired vascular reactivity to carbon dioxide may also exaggerate the accumulation and washout of carbon dioxide from central chemoreceptors causing breathing instability during sleep. Ryan A guinea pig animal model has shown that recurrent apneas result in cell death by apoptosis in the hippocampus and forebrain regions. 185 Such neuronal damage can lead to cognitive impairment. 186, 187 Indeed, altered neuronal metabolism during nocturnal oxygen desaturations in OSA has been demonstrated. 188 Furthermore, consistent with neuronal damage, deficits in executive function and verbal memory occur particularly in those with moderate to severe OSA. 186, 187, 189 Overt cerebral damage is not obvious on routine MRI scans for most subjects with OSA. However, newer MRI modalities including spectroscopy and diffusion tensor imaging demonstrate white matter injury (leukoaraiosis) compared to controls 190 in addition to regional grey matter loss in OSA subjects. 189, [191] [192] [193] Leukoaraiosis is a strong predictor of both stroke risk and outcome from stroke 194 and interestingly two recent small studies have suggested that leukoaraiosis may result from white matter infarction in some instances. 195, 196 Canessa et al also demonstrated that cognitive impairment associated with grey matter volume reduction can be reversed by treatment of the OSA and that these structural brain abnormalities occurred in regions susceptible to hypoxic injury. 193 In summary, the presence of OSA may cause alterations in cerebral perfusion, response of cerebral blood vessels to insult, and neuronal cell damage in susceptible brain tissue, which can predispose to increased stroke risk.
How to determine presence of OSA in stroke subjects?
Determination of the presence or absence of OSA in stroke subjects is difficult without the performance of an overnight in-laboratory or portable sleep study. 197 Traditional symptoms including daytime sleepiness and snoring may be absent. Arzt and colleagues showed that compared to a community sample, those subjects with stroke with or without OSA had less subjective daytime sleepiness as measured by the Epworth sleepiness scale and lower body mass index. 198 Both the absence of daytime sleepiness and lower body mass index is also seen in many of the observational studies. 18 The Berlin Questionnaire is a validated questionnaire for the determination of OSA risk. 199 Yet, in the acute stroke population it failed to predict those at high risk of OSA (positive predictive value 63.4%, negative predictive value 58.8%). 200 The presence of nocturia may help identify those with OSA. In a prospective study of 65 consecutive subjects with ischemic stroke, nocturia was an independent predictor of severe OSA (OR = 3.5). 201 Results from a meta-analysis indicate that recurrent stroke may also be an indicator of the presence of OSA. 18 Determination of the presence or absence of OSA in stroke patients through history and examination may be inaccurate, and reliance on the usual predictors of stroke in this population is not recommended.
Conclusion
In summary, the epidemiology evidence suggests a significant relationship between OSA and stroke and there are multiple pathophysiological pathways by which OSA may predispose to stroke. In view of the significant toll of stroke on the individual and society it is imperative that the medical community continue to develop strategies for both prevention and intervention in stroke. Strategies for comprehensive acute, chronic and preventive care of stroke should be complemented with evaluation for the presence or absence of OSA. Recent clinical studies have bolstered the evidence for the treatment of those with moderate to severe OSA in the general population. In patients who have sustained a cerebrovascular event there is evidence of a potential benefit by treatment with CPAP. There are key pathophysiological mechanisms which can explain the deleterious effect of OSA on the brain. However, further research is needed to: (1) identify those subjects with OSA most at risk of stroke; (2) in the post-stroke population have testing strategies to quickly and easily identify those with OSA; (3) determine those who would benefit most from treatment and (4) develop alternative modalities of treatment which would be better tolerated by the stroke population. 
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